预约演示

Orion to hand over exclusive rights to MSD for prostate cancer therapy

2024-07-01

交易

引进/卖出临床3期临床终止临床2期

The non-steroidal, selective CYP11A1 inhibitor opevesostat is being studied in two pivotal Phase III trials, OMAHA1 and OMAHA2. Credits: Tada Images/Shutterstock.com

Merck & Co (MSD) has announceCYP11A1 inhibitor CYP11A1its ongoingopevesostatwith Orion Corporation for the co-development and co-commercialisation of opevesostat (MK-5684/ODM-208) has changed to give MSD exclusive rights to the investigational hormone-dependent cancer treatment.

Merck & CoteMSD of the original agreement, both MSD and Orion hOrion Corporationconvert the licensing agreement into an exclusive glopevesostate for MSD. A wholly exclusive license aMSDement would give MSD exclusive rights forhormone-dependent cancerand commercialisation of opevesostat and other CYP11A1 inhibitor-targeting candidates. Consequently, Orion is now in a position to receive up to $30m for developmental milestones, up to $625m for regulatory milestones, and up to $975m for sales-contingent milestones.

Changing the agreement with MSD allows Orion to MSDocate its resources to advance other projects while maximising the potential of opevesostat for thMSDreatment of certain prostate cancers and reaping tMSDdevelopmental and commercial benefits of the candidate, Orion presidenopevesostatLiisa HurmeCYP11A1 inhibitor CYP11A1n the 1 July press release.

Espoo, Finland-based Orion wMSD also continue to be responsible for the drug manufacturing for the clinical and commercial supply fopevesostat prostate cancers

Opevesostat, a non-steroidal, selective CYP11A1 inhibitor, is designed to suppress the production of steroid hormones that may induce the androgen receptor signalling pathway activated in hormone-dependent cancers such as prostate cancer. The treatment is actively being evaluated in two pivotal Phase III studies, OMAHA1 (NCT06136624) and OMAHA2a (NCT06136650).

Opevesostatsai and Bristol Myers Squibb CYP11A1 inhibitor CYP11A1te ADC development dealandrogen receptor hormone-dependent cancers prostate cancer

Orion to Eisaiover Bristol Myers SquibbMSD for proADCte cancer therapy

According to GlobalData’s consensus forecasts, opevesostat is expected to generate global sales of $207m in 2030. GlobalData is the parent company of Pharmaceutical Technology.

The randomised, open-label OMAHA1 compaMSD the prostate cancermone replacement therapy (HRT) combination therapy to an alternative next-generation hormonal agent (NHA) like abiraterone acetate or enzalutamide. The study is recruiting patients with metastatic castration-resistant prostate cancer (mCRPC) who have failed a prior line of NHAs or two prior taxanes. Johnson and Johnson markets abiraterone as Zytiga while enzalutamide is sold as Xtandi by Pfizer and Astellas Oncology. The primary endpoints of this study are overall survival and radiographic progression-free survival (rPFS) in androgen receptor ligand-binding domain (AR LBD) mutation status patients.

OMAHA2a is studying the safety and efficacy of combination therapy compared to Xtandi or Zytica for the treatment of patients with front-line mCRPC who have failed a prior line of an NHA.

Earlier this year, MSD signed a clinical trial opevesostaton and supply agreement with Lava Therapeutics to study Lava’s prostate cancer therapy, LAVAPharmaceutical Technologybination treatment with the former’s blockbuster drug Keytruda (pembrolizumab).

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构